Pharmaceuticals, Biotechnology & Life Sciences

Prothena insider buying: SCULLY WILLIAM P adds 100k shares, boosting stake to 27% – a bullish sign amid price dips, pipeline hype & potential catalysts.

Insider buying heats up ANIXA BIOSCIENCES—Titterton Lewis H. Jr. buys 8,000 shares at $2.98 amid a 12.26% weekly gain, 30.9% YTD volatility, and rising buzz.

Inside Acrivon’s latest insider sale: Miller Mary’s tax‑withholding trade shows steady executive confidence while the company’s proteomics pipeline drives future value.

EXOZYMES insider purchase shows cautious optimism amid biotech volatility – a key insight for investors eyeing near‑term pipeline and market‑access milestones.

Inside Natera: Insider selling spiked by Sheena Jonathan, yet company fundamentals and positive sentiment keep the stock on an upward trajectory. Discover what this means for investors.

Charles River Laboratories insider trade shows disciplined Rule 10b5‑1 use—buy & sell on 21 Oct, no net change, but signals confidence in future R&D growth.

Insider CFO John Borgeson’s 10‑b5‑1 trades show disciplined, buy‑low‑sell‑high moves amid strong institutional buying, highlighting Kodiak Sciences’ long‑term strategy.

CEO’s 2,210‑share sale at $29.16 sparks debate—insider liquidity vs. confidence, amid rising insider buying and volatile stock price at Rapport Therapeutics.

MEDPACE insider buy: Exec. VP Susan Burwig snaps up 2,700 shares at $166.73, a discount to $654, signaling confidence in a growing, tech‑driven healthcare cash flow.

Agios insider sales reveal disciplined portfolio management, not a bearish signal—see how Gheuens’ 10b5‑1 trades align with pipeline progress and market sentiment.